You are here:

icatibant (Firazyr)

Advice

following a resubmission

icatibant acetate (Firazyr®) is accepted for use within NHS Scotland.

Indication under review: Symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

Icatibant treatment resulted in symptom relief in patients suffering acute abdominal, cutaneous and/or laryngeal attacks of hereditary angioedema.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of icatibant. This SMC advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland.

Drug Details

Drug Name: icatibant (Firazyr)
SMC Drug ID: 476/08
Manufacturer: Shire Pharmaceuticals
Indication: for the treatment of symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (type I and II HAE).
BNF Category:
Sub Category: 3.4 Antihistamines hyposensitisation and allergic emergencies
Submission Type: Resubmission
Status: Accepted
Date Advice Published: 12 March 2012

Archived Advice

Full submission 10 November 2008

Back